• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

BC-007: Successful drug against Autoantibodies helps with long COVID

Hufsamor

Senior Member
Messages
2,793
Location
Norway
https://www.archyde.com/worlds-firs...0Z639fFuiUwcXUlJVsLvR-m9lfw7FkMQM5kDlKVkPPrMo

Thanks to a drug that was originally developed to combat heart disease, a team of doctors at the Eye Clinic (Director: Prof. Dr. Friedrich E. Kruse) at the Erlangen University Hospital has now succeeded for the first time as part of an individual healing attempt that a 59-year-old man with Long COVID Syndrome became symptom-free.
Whether the active ingredient BC 007 also helps other sufferers will soon be examined in a clinical study. “At the moment, unfortunately, we can no longer treat people with the drug because it has not yet passed all approval studies,” says Prof. Dr. Christian Mardin, senior physician in charge of the eye clinic.
 

Martin aka paused||M.E.

Senior Member
Messages
2,291
https://www.archyde.com/worlds-firs...0Z639fFuiUwcXUlJVsLvR-m9lfw7FkMQM5kDlKVkPPrMo

Thanks to a drug that was originally developed to combat heart disease, a team of doctors at the Eye Clinic (Director: Prof. Dr. Friedrich E. Kruse) at the Erlangen University Hospital has now succeeded for the first time as part of an individual healing attempt that a 59-year-old man with Long COVID Syndrome became symptom-free.
Whether the active ingredient BC 007 also helps other sufferers will soon be examined in a clinical study. “At the moment, unfortunately, we can no longer treat people with the drug because it has not yet passed all approval studies,” says Prof. Dr. Christian Mardin, senior physician in charge of the eye clinic.
Berlin Cures had a hard time to get funded by the German government. Hopefully that changes now
 

dylemmaz

Senior Member
Messages
136
Some report that the blood vessels in the eyes get broken sometimes and of increased eye pressure. I don't have this
interesting. probably just another thing that hasn’t been studied in cfs because of how much the medical establishment loves us!

it is nice to imagine taking a drug and being cured. let’s all hope for positive results from the clinical trial
 

SWAlexander

Senior Member
Messages
1,985
Long-Covid Patient Succesfully Treated With BC 007
BC 007 was successfully used for the treatment of a Long-Covid Patient at Erlangen University. The 59y male patient suffered from fatigue and other typical long-covid symptoms. He was positive for different GPCR-autoantibodies. After a single treatment, the symptoms improved dramatically and the microcirculation, as measured in retinal angiography, also improved significantly. https://berlincures.de/long-covid-p...vid-patient-erfolgreich-mit-bc-007-behandelt/
 

Pyrrhus

Senior Member
Messages
4,172
Location
U.S., Earth
Last edited:

Pyrrhus

Senior Member
Messages
4,172
Location
U.S., Earth
Long-Covid Patient Succesfully Treated With BC 007
BC 007 was successfully used for the treatment of a Long-Covid Patient at Erlangen University. The 59y male patient suffered from fatigue and other typical long-covid symptoms. He was positive for different GPCR-autoantibodies. After a single treatment, the symptoms improved dramatically and the microcirculation, as measured in retinal angiography, also improved significantly. https://berlincures.de/long-covid-p...vid-patient-erfolgreich-mit-bc-007-behandelt/

Published case report:

Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection (Hohberger et al., 2021)
https://www.frontiersin.org/articles/10.3389/fmed.2021.754667/full

Excerpt:
Clinical features of Coronavirus disease 2019 (COVID-19) are caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Acute infection management is a substantial healthcare issue, and the development of long-Covid syndrome (LCS) is extremely challenging for patients and physicians. It is associated with a variety of characteristics as impaired capillary microcirculation, chronic fatigue syndrome (CFS), proinflammatory cytokines, and functional autoantibodies targeting G-protein-coupled receptors (GPCR-AAbs).

Here, we present a case report of successful healing of LCS with BC 007 (Berlin Cures, Berlin, Germany), a DNA aptamer drug with a high affinity to GPCR-AAbs that neutralizes these AAbs. A patient with a documented history of glaucoma, recovered from mild COVID-19, but still suffered from CFS, loss of taste, and impaired capillary microcirculation in the macula and peripapillary region. He was positively tested for various targeting GPCR-AAbs.

Within 48 h after a single BC 007 treatment, GPCR-AAbs were functionally inactivated and remained inactive during the observation period of 4 weeks. This observation was accompanied by constant improvement of the fatigue symptoms of the patient, taste, and retinal capillary microcirculation. Therefore, the removal of GPCR-AAb might ameliorate the characteristics of the LCD, such as capillary impairment, loss of taste, and CFS.
 

SWAlexander

Senior Member
Messages
1,985
As Carmen Scheibenbogen’s group was tracking down autoantibodies that affect the blood vessel functioning in chronic fatigue syndrome (ME/CFS), a small German group called Berlin Cures was using a different assay to assess the same autoantibodies in heart failure.

They had a drug called BC 007 that’s able to bind to and neutralize autoantibodies that attach to the G-protein-coupled receptors (GPCRs). Their 2016 paper claimed their new approach was easier and possibly more effective than past treatments such as immunoadsorption that have been used to mop up these autoantibodies.
More at:
https://www.healthrising.org/blog/2...in-cures-long-covid-chronic-fatigue-syndrome/
 

perrier

Senior Member
Messages
1,254
FYI: I just saw a post on twitter (don't know the rules on reposting) that Berlin Cures is not doing any study on ME, which means that in their current study they will not have ME patients. They are working entirely on LC.
 
Back